1-6 of 6
Victor M. Rivera
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1268–1276.
https://doi.org/10.1158/1078-0432.CCR-21-2037
Published: 01 April 2022
View article titled, Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Open the PDF for Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers in another window
Includes: Supplementary data
Journal Articles

Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias

Michael W. Schmitt, Justin R. Pritchard, Scott M. Leighow, Bella I. Aminov, Lan Beppu, Daniel S. Kim, J. Graeme Hodgson, Victor M. Rivera, Lawrence A. Loeb, Jerald P. Radich
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (21): 5321–5334.
https://doi.org/10.1158/1078-0432.CCR-18-0167
Published: 01 November 2018
View article titled, Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias
Open the PDF for Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias in another window
Includes: Supplementary data
Journal Articles

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D. Wardwell, David Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei-Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana Narasimhan, Frank Wang, Juan Miret, Xiaotian Zhu, Tim Clackson, David Dalgarno, William C. Shakespeare, Victor M. Rivera
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5527–5538.
https://doi.org/10.1158/1078-0432.CCR-16-0569
Published: 14 November 2016
View article titled, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Open the PDF for The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (22): 5745–5755.
https://doi.org/10.1158/1078-0432.CCR-14-1397
Published: 13 November 2014
View article titled, Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Open the PDF for Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Christine M. Hartford, Apurva A. Desai, Linda Janisch, Theodore Karrison, Victor M. Rivera, Lori Berk, John W. Loewy, Hedy Kindler, Walter M. Stadler, Heather L. Knowles, Camille Bedrosian, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1428–1434.
https://doi.org/10.1158/1078-0432.CCR-08-2076
Published: 19 February 2009
View article titled, A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Open the PDF for A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies in another window
Journal Articles

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

David A. Rizzieri, Eric Feldman, John F. DiPersio, Nashat Gabrail, Wendy Stock, Roger Strair, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2756–2762.
https://doi.org/10.1158/1078-0432.CCR-07-1372
Published: 01 May 2008
View article titled, A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies in another window